SCHEMBL27199384

SCHEMBL27199384

CCn1ccc2c(c(I)nn2C)c1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
MAPK13 O15264 1/20 0.32
EIF2AK2 P19525 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
GRM2 Q14416 3/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
TSHR P16473 2/20 0.32
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27199399 0.83 PDE5A (0.36) KDM4EALDH1A1MAPK1MAPK13EIF2AK2
Hydrochloric Acid SCHEMBL27199638 0.81 PDE5A (0.35) KDM4EALDH1A1MAPK1MAPK13EIF2AK2
SCHEMBL27199473 0.75 ALDH1A1 (0.39) KDM4EALDH1A1LMNAHTTMAPT
SCHEMBL25757053 0.75 CNR1 (0.34) KDM4ELMNAHTTTSHRMAPT
SCHEMBL25670768 0.73 ALDH1A1 (0.33) KDM4EALDH1A1MAPK1TSHR
SCHEMBL27199496 0.73 CNR1 (0.35) KDM4EGRM2LMNAHTTTSHR
SCHEMBL25757052 0.72 PDE4A (0.33) KDM4EALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL25670818 0.70 ALDH1A1 (0.33) KDM4EALDH1A1MAPK1TSHR
Hydrochloric Acid SCHEMBL27199382 0.69 ALDH1A1 (0.33) KDM4EALDH1A1MAPK1TSHRMAPT
SCHEMBL27199454 0.66 JAK2 (0.35) MAPK13EIF2AK2MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 KDM4E 404/4885ALDH1A1 4805/4885MAPK1 372/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 KDM4E 404/4885ALDH1A1 4805/4885MAPK1 372/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 KDM4E 404/4885ALDH1A1 4805/4885MAPK1 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.